Novocure Ltd (NVCR NASDAQ) stock market data APIs
$19.0252
-0.19(-1%)
as of March 19, 2025
Novocure Ltd Financial Data Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
19.217
Open
19.0252
High
19.7373
Low
19.0252
52 wk Range
11.7-34.13
Market Cap
2 124 M
Shares Outstanding
110 M
Revenue
605 M
EPS
-0.61
Beta
0.628
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 605 M
- EBITDA: -157 672 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-27
- EPS/Forecast: -0.3445
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
BAAR, Switzerland, March 04, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Chr...
NovoCure Full Year 2024 Earnings: EPS Misses Expectations
NovoCure (NASDAQ:NVCR) Full Year 2024 Results Key Financial Results Revenue: US$605.2m (up 19% from FY 2023). Net loss: US$168.6m (loss narrowed by 19% from FY 2023). US$1.56 loss per share (improve...
NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...
Revenue (Q4 2024): $161 million, a 21% increase compared to Q4 2023. Revenue (Full Year 2024): $605 million, a 19% increase year-over-year. Gross Margin (Q4 2024): 79%. Gross Margin (Full Year 2024): ...
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
NovoCure (NVCR) reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a year ag...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
